India's Union Health Ministry has banned the manufacture, sale, and distribution of all oral formulations of the painkiller Nimesulide above 100 mg in immediate-release dosage form, citing serious health risks and the availability of safer alternatives. The decision, effective immediately, was made under Section 26A of the Drugs and Cosmetics Act, 1940, following recommendations from the Indian Council of Medical Research (ICMR) and consultation with the Drugs Technical Advisory Board (DTAB). Nimesulide has faced global scrutiny for potential liver toxicity and other adverse effects. Lower-dose formulations and non-oral forms remain available.